---
title: "BUZZ-Bristol Myers drops after Reuters reports no ongoing AstraZeneca deal talks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294966486.md"
datetime: "2026-08-05T12:21:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294966486.md)
  - [en](https://longbridge.com/en/news/294966486.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294966486.md)
---

# BUZZ-Bristol Myers drops after Reuters reports no ongoing AstraZeneca deal talks

Shares of Bristol Myers Squibb (BMY.N) fall 2.2% to $64.46 premarket There are “no discussions” ongoing between AstraZeneca (AZN.L) and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters

“There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies,” said the source Reuters had earlier reported that initial discussions had taken place, but it was unclear whether talks were still ongoing

U.S.-listed shares of AstraZeneca (AZN.N) jumped 5.8% before the bell

As of last close, BMY up 22.2% YTD

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Ascent Group LLC Has $3.21 Million Stake in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/295994083.md)
- [AstraZeneca held talks with Bristol-Myers through spring, summer - FT](https://longbridge.com/en/news/295571239.md)
- [FDA grants accelerated approval to Bristol Myers Squibb’s ZENBEXUS for relapsed multiple myeloma combo use](https://longbridge.com/en/news/295848217.md)
- [Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene](https://longbridge.com/en/news/296131073.md)
- [Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment](https://longbridge.com/en/news/295957550.md)